AIMS/HYPOTHESIS: Established autoimmune markers of type 1 diabetes, including islet cell autoantibodies (ICA) and autoantibodies to glutamic acid decarboxylase (GADA) have been used to screen people presenting with type 2 diabetes for latent autoimmune diabetes in adults. We have examined the prevalence of autoantibodies to protein tyrosine phosphatase isoforms IA-2 (IA-2A) and IA-2beta/phogrin (IA-2betaA) in a cohort of adult UKPDS patients thought to have type 2 diabetes, and investigated the possible role of these autoantibodies in predicting requirement for insulin therapy. METHODS: IA-2A and IA-2betaA were measured by a validated radioimmunoassay with human recombinant autoantigens in 4,169 white Caucasian patients aged 25-65 years and newly diagnosed with type 2 diabetes. The clinical requirement for insulin therapy within 6 years was examined in 2,556 patients not randomised to insulin. RESULTS: IA-2A and IA-2betaA were present in 2.2 and 1.4%, respectively, of these patients. IA-2A were more prevalent in younger patients (p for trend <0.00001), more often associated with the HLA-DR4 allele (26.3 vs 8.0%, p<0.0001), and their presence increased the likelihood of insulin therapy requirement within 6 years from diagnosis [relative risk (95%CI) 12.2 (9.8-15.3)]. The presence of IA-2A together with GADA increased the relative risk of requiring insulin therapy from 5.4 (4.1-7.1) for GADA alone to 8.3 (3.7-18.8) and the corresponding positive predictive value from 33 to 50%. CONCLUSIONS/ INTERPRETATION: In type 2 diabetes, the presence of IA-2A is infrequent, associated with the HLA-DR4 haplotype, and highly predictive of future need for insulin therapy. The measurement of IA-2betaA does not provide additional information.
AIMS/HYPOTHESIS: Established autoimmune markers of type 1 diabetes, including islet cell autoantibodies (ICA) and autoantibodies to glutamic acid decarboxylase (GADA) have been used to screen people presenting with type 2 diabetes for latent autoimmune diabetes in adults. We have examined the prevalence of autoantibodies to protein tyrosine phosphatase isoforms IA-2 (IA-2A) and IA-2beta/phogrin (IA-2betaA) in a cohort of adult UKPDS patients thought to have type 2 diabetes, and investigated the possible role of these autoantibodies in predicting requirement for insulin therapy. METHODS:IA-2A and IA-2betaA were measured by a validated radioimmunoassay with human recombinant autoantigens in 4,169 white Caucasian patients aged 25-65 years and newly diagnosed with type 2 diabetes. The clinical requirement for insulin therapy within 6 years was examined in 2,556 patients not randomised to insulin. RESULTS:IA-2A and IA-2betaA were present in 2.2 and 1.4%, respectively, of these patients. IA-2A were more prevalent in younger patients (p for trend <0.00001), more often associated with the HLA-DR4 allele (26.3 vs 8.0%, p<0.0001), and their presence increased the likelihood of insulin therapy requirement within 6 years from diagnosis [relative risk (95%CI) 12.2 (9.8-15.3)]. The presence of IA-2A together with GADA increased the relative risk of requiring insulin therapy from 5.4 (4.1-7.1) for GADA alone to 8.3 (3.7-18.8) and the corresponding positive predictive value from 33 to 50%. CONCLUSIONS/ INTERPRETATION: In type 2 diabetes, the presence of IA-2A is infrequent, associated with the HLA-DR4 haplotype, and highly predictive of future need for insulin therapy. The measurement of IA-2betaA does not provide additional information.
Authors: V Horton; I Stratton; G F Bottazzo; M Shattock; I Mackay; P Zimmet; S Manley; R Holman; R Turner Journal: Diabetologia Date: 1999-05 Impact factor: 10.122
Authors: S Genovese; R Bonfanti; E Bazzigaluppi; V Lampasona; E Benazzi; E Bosi; G Chiumello; E Bonifacio Journal: Diabetologia Date: 1996-10 Impact factor: 10.122
Authors: E Bakhtadze; H Borg; G Stenström; P Fernlund; H J Arnqvist; A Ekbom-Schnell; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; L C Groop; G Sundkvist Journal: Diabetologia Date: 2006-05-31 Impact factor: 10.122
Authors: Wassim Y Almawi; Saria F Wakim-Ghorayeb; Mona R Arekat; Pierre Najm; Sose H Keleshian; Nasreen Al-Sayed; Bruno Blanchon; Hanady R Samaha; Noha Irani-Hakime Journal: Clin Vaccine Immunol Date: 2006-09-20
Authors: Martín E Noguera; María E Primo; Jean Jakoncic; Edgardo Poskus; Michele Solimena; Mario R Ermácora Journal: J Struct Funct Genomics Date: 2014-11-26
Authors: M Desai; C A Cull; V A Horton; M R Christie; E Bonifacio; V Lampasona; P J Bingley; J C Levy; I R Mackay; P Zimmet; R R Holman; A Clark Journal: Diabetologia Date: 2007-07-27 Impact factor: 10.122
Authors: Vito Lampasona; Antonio Petrone; Claudio Tiberti; Marco Capizzi; Marialuisa Spoletini; Sergio di Pietro; Marco Songini; Sara Bonicchio; Francesco Giorgino; Ezio Bonifacio; Emanuele Bosi; Raffaella Buzzetti Journal: Diabetes Care Date: 2009-10-06 Impact factor: 19.112